1158 related articles for article (PubMed ID: 26861783)
1. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
[TBL] [Abstract][Full Text] [Related]
2. Renal Handling of Ketones in Response to Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 2 Diabetes.
Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Barsotti E; Clerico A; Muscelli E
Diabetes Care; 2017 Jun; 40(6):771-776. PubMed ID: 28325783
[TBL] [Abstract][Full Text] [Related]
3. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ferrannini E; Muscelli E; Frascerra S; Baldi S; Mari A; Heise T; Broedl UC; Woerle HJ
J Clin Invest; 2014 Feb; 124(2):499-508. PubMed ID: 24463454
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes.
Heise T; Seewaldt-Becker E; Macha S; Hantel S; Pinnetti S; Seman L; Woerle HJ
Diabetes Obes Metab; 2013 Jul; 15(7):613-21. PubMed ID: 23356556
[TBL] [Abstract][Full Text] [Related]
5. Metabolic consequences of acute and chronic empagliflozin administration in treatment-naive and metformin pretreated patients with type 2 diabetes.
Muscelli E; Astiarraga B; Barsotti E; Mari A; Schliess F; Nosek L; Heise T; Broedl UC; Woerle HJ; Ferrannini E
Diabetologia; 2016 Apr; 59(4):700-8. PubMed ID: 26704626
[TBL] [Abstract][Full Text] [Related]
6. Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.
Al Jobori H; Daniele G; Adams J; Cersosimo E; Triplitt C; DeFronzo RA; Abdul-Ghani M
Diabetes Obes Metab; 2017 Jun; 19(6):809-813. PubMed ID: 28128510
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter-2 inhibition improves incretin sensitivity of pancreatic β-cells in people with type 2 diabetes.
Ahn CH; Oh TJ; Kwak SH; Cho YM
Diabetes Obes Metab; 2018 Feb; 20(2):370-377. PubMed ID: 28786557
[TBL] [Abstract][Full Text] [Related]
8. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
[TBL] [Abstract][Full Text] [Related]
9. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
[TBL] [Abstract][Full Text] [Related]
10. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
11. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
12. Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Scheen AJ; Paquot N
Diabetes Metab; 2014 Dec; 40(6 Suppl 1):S4-S11. PubMed ID: 25554070
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
[TBL] [Abstract][Full Text] [Related]
14. Endogenous Glucose Production and Hormonal Changes in Response to Canagliflozin and Liraglutide Combination Therapy.
Martinez R; Al-Jobori H; Ali AM; Adams J; Abdul-Ghani M; Triplitt C; DeFronzo RA; Cersosimo E
Diabetes; 2018 Jun; 67(6):1182-1189. PubMed ID: 29602791
[TBL] [Abstract][Full Text] [Related]
15. [Glucose renal excretion as diabetes treatment: From an old diagnostic method to a new way of treatment].
Dalama B; Biagetti B; Mesa J
Med Clin (Barc); 2016 May; 146(10):460-4. PubMed ID: 26823105
[No Abstract] [Full Text] [Related]
16. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition.
Ferrannini G; Hach T; Crowe S; Sanghvi A; Hall KD; Ferrannini E
Diabetes Care; 2015 Sep; 38(9):1730-5. PubMed ID: 26180105
[TBL] [Abstract][Full Text] [Related]
17. Empagliflozin as add-on to metformin in people with Type 2 diabetes.
Merker L; Häring HU; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabet Med; 2015 Dec; 32(12):1555-67. PubMed ID: 26031566
[TBL] [Abstract][Full Text] [Related]
18. The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition.
Hædersdal S; Lund A; Nielsen-Hannerup E; Maagensen H; van Hall G; Holst JJ; Knop FK; Vilsbøll T
Diabetes; 2020 Dec; 69(12):2619-2629. PubMed ID: 33004472
[TBL] [Abstract][Full Text] [Related]
19. Place of sodium-glucose cotransporter-2 inhibitors in East Asian subjects with type 2 diabetes mellitus: Insights into the management of Asian phenotype.
Lim LL; Tan AT; Moses K; Rajadhyaksha V; Chan SP
J Diabetes Complications; 2017 Feb; 31(2):494-503. PubMed ID: 27866701
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials.
Tang H; Li D; Zhang J; Li Y; Wang T; Zhai S; Song Y
Diabetes Obes Metab; 2017 Aug; 19(8):1106-1115. PubMed ID: 28240446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
